epiberberine has been researched along with chloroquine in 1 studies
| Studies (epiberberine) | Trials (epiberberine) | Recent Studies (post-2010) (epiberberine) | Studies (chloroquine) | Trials (chloroquine) | Recent Studies (post-2010) (chloroquine) |
|---|---|---|---|---|---|
| 49 | 0 | 37 | 16,405 | 763 | 4,029 |
| Protein | Taxonomy | epiberberine (IC50) | chloroquine (IC50) |
|---|---|---|---|
| glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | Plasmodium berghei | 43 | |
| Spike glycoprotein | Betacoronavirus England 1 | 5.47 | |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | 5.47 | |
| Transmembrane protease serine 2 | Homo sapiens (human) | 5.47 | |
| Dihydrofolate reductase | Bos taurus (cattle) | 0.0301 | |
| Amyloid-beta precursor protein | Homo sapiens (human) | 7 | |
| Histidine-rich protein PFHRP-II | Plasmodium falciparum (malaria parasite P. falciparum) | 0.2383 | |
| Procathepsin L | Homo sapiens (human) | 5.47 | |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
| Replicase polyprotein 1ab | Human coronavirus 229E | 5.47 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
| Spike glycoprotein | Severe acute respiratory syndrome coronavirus 2 | 3.58 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 6.375 | |
| Ribosyldihydronicotinamide dehydrogenase [quinone] | Homo sapiens (human) | 1.5 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.27 | |
| Beta-secretase 1 | Homo sapiens (human) | 7 | |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 2.503 | |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | 6.235 | |
| Cysteine proteinase falcipain 2a | Plasmodium falciparum (malaria parasite P. falciparum) | 0.02 | |
| Cysteine proteinase falcipain 2a | Plasmodium falciparum (malaria parasite P. falciparum) | 0.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y | 1 |
1 other study(ies) available for epiberberine and chloroquine
| Article | Year |
|---|---|
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Topics: Animals; Antimalarials; Cell Line, Tumor; Drug Discovery; Drug Evaluation, Preclinical; Drug Resistance; Erythrocytes; Humans; Imidazoles; Liver; Malaria; Mice; Mice, Inbred BALB C; Molecular Structure; Piperazines; Plasmodium; Plasmodium berghei; Plasmodium falciparum; Plasmodium yoelii; Polymorphism, Single Nucleotide; Protozoan Proteins; Random Allocation; Small Molecule Libraries; Sporozoites | 2011 |